PMID- 21048493
OWN - NLM
STAT- MEDLINE
DCOM- 20111012
LR  - 20110627
IS  - 1473-5741 (Electronic)
IS  - 0959-4973 (Linking)
VI  - 22
IP  - 7
DP  - 2011 Aug
TI  - New advances in targeted therapies for squamous cell carcinoma of the head and 
      neck.
PG  - 626-33
LID - 10.1097/CAD.0b013e328341071e [doi]
AB  - Several molecular pathways are deregulated and activated in squamous cell 
      carcinoma of the head and neck making this disease attractive for targeted 
      molecular therapies. Cetuximab, a monoclonal antibody that binds to the epidermal 
      growth factor receptor, improves the overall survival when combined with 
      radiation therapy or chemotherapy. Novels agents targeting different molecular 
      pathways in squamous cell carcinoma of the head and neck are currently under 
      development. Among them, dual (epidermal growth factor receptor/human epidermal 
      growth factor receptor-2) or pan-human epidermal growth factor receptor 
      inhibitors and drugs that target the insulin growth factor-1 receptor, the MET 
      receptor, or the phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of 
      rapamycin (mTOR) pathway have shown either interesting preclinical activity or 
      promising preliminary clinical efficacy. Angiogenesis inhibitors should be used 
      with caution in squamous cell carcinoma of the head and neck due to the risk of 
      tumor bleeding. However, only a minority of patients seems to benefit from these 
      new approaches. Understanding the primary and acquired resistance mechanisms to 
      predict the treatment efficacy is of crucial importance to allow a better patient 
      selection.
FAU - Machiels, Jean-Pascal
AU  - Machiels JP
AD  - Centre du Cancer, Department of Medical Oncology, Clinique de Cancerologie 
      Cervico-maxillo-faciale, Cliniques Universitaires Saint-Luc, Universite 
      Catholique de Louvain, Brussels, Belgium. pointr_y@yahoo.fr
FAU - Schmitz, Sandra
AU  - Schmitz S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Angiogenesis Inhibitors/adverse effects/pharmacology/therapeutic use
MH  - Animals
MH  - Antineoplastic Agents/adverse effects/*pharmacology/therapeutic use
MH  - Carcinoma, Squamous Cell/*drug therapy/physiopathology
MH  - Drug Design
MH  - Drug Resistance, Neoplasm
MH  - Head and Neck Neoplasms/*drug therapy/physiopathology
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Patient Selection
EDAT- 2010/11/05 06:00
MHDA- 2011/10/13 06:00
CRDT- 2010/11/05 06:00
PHST- 2010/11/05 06:00 [entrez]
PHST- 2010/11/05 06:00 [pubmed]
PHST- 2011/10/13 06:00 [medline]
AID - 10.1097/CAD.0b013e328341071e [doi]
PST - ppublish
SO  - Anticancer Drugs. 2011 Aug;22(7):626-33. doi: 10.1097/CAD.0b013e328341071e.